



3rd February, 2026

Wanbury Limited

Regd. Office : BSEL Tech Park, B-wing
10th Floor, Sector-30 A,
Opp. Vashi Railway Station,
Vashi Navi Mumbai 400 703
Maharashtra, INDIA
Tel. : +91-22-6794 2222
+91-22-7196 3222
Fax : +91-22-6794 2111/333
CIN L51900MH1988PLC048455
Email : info@wanbury.com
Website : www.wanbury.com

BSE Limited PJ. Towers, Dalal Street Mumbai – 400 001. Script Code: 524212	National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051. Script Code: WANBURY
---	--

Dear Sir/Madam,

Sub: Press Release

Please find attached a Press Release with titled “Wanbury Achieves First Sales Invoicing and commercial shipment Milestone on 30th January, 2026 for the new product, High - Demand Anaesthetic API- Production Ramp-Up Signals Rapid Growth Ahead”.

This is for your information and record.

Thanking you.

Yours faithfully,
For Wanbury Ltd



Jitendra J. Gandhi
Company Secretary



Wanbury Achieves First Sales Invoicing and commercial shipment Milestone on 30th January, 2026 for the new product, High-Demand Anaesthetic API- Production Ramp-Up Signals Rapid Growth Ahead.

Mumbai, February 3, 2026 - Wanbury Limited, a leading player in Active Pharmaceutical Ingredients (APIs), and branded formulations today celebrated a game-changing milestone: official confirmation of first sales, customer invoicing and commercial shipment to European customer for its newly commercialized anaesthetic API from the cutting-edge Tanuku facility. This achievement validates global demand and catapults Wanbury into high-growth acceleration. Just months after launching commercial production, Wanbury has secured orders and completed invoicing and product shipment, a clear testament to our operational excellence and market-leading product quality. This success story is set to multiply as we ramp up production capacity at Tanuku.

"First sales confirmed, invoicing and product shipment completed, production scaling fast. Our expansion momentum positions us for exponential growth and market leadership." declared by Mr. Mohan Rayana, Whole-time Director of Wanbury Limited.



About Wanbury Ltd.

Established in 1988, listed on the National Stock Exchange of India Ltd (Code: WANBURY) and BSE Ltd (Code: 524212). The company has a strong presence in API global market and domestic branded Formulation with its API being exported to over 50 countries and has Pan-India Formulation presence. The company has USFDA & EUGMP approved facilities at Tanuku (Andhra Pradesh) and Patalganga (Maharashtra).

The API product portfolio includes: Metformin, Sertraline, Tramadol, Diphenhydramine, Mefenamic acid, Paroxetine, Ketamine Hydrochloride and various other products in pipeline. The company's clients include some of the leading global generic players.

In formulations, the company has a wide presence across major therapeutic categories like, cough and cold solutions, gynaecology, orthopaedics, nutraceuticals, gastro intestinal, anti-inflammatory, & analgesics.

For more details on Wanbury Ltd.: <https://www.wanbury.com/>

For further information please contact

Jitendra J. Gandhi
Company Secretary,
Wanbury Limited
BSEL Techpark,B' Wing, 10th Floor,
Sector 30-A,Opp. Vashi Railway Station,
Vashi, Navi Mumbai - 400703, India.
Tel: +91-22-6794 2222
Email: [jitendra.gandhi@wanbury.com](mailto: jitendra.gandhi@wanbury.com)

Hanishi Shah / Anand Venugopal
Adfactors PR
Oasis Complex, Kamala Mills Compound,
City Hall, Pandurang Budhkar Marg, Lower
Parel West, Mumbai - 400021
Tel: +91 9619059339 / +91 7021852071
Email: [hanishi.shah@adfactorspr.com](mailto: hanishi.shah@adfactorspr.com)
 [anand.venugopal@adfactorspr.com](mailto: anand.venugopal@adfactorspr.com)

Disclaimer:

This document may contain statements which reflect management's current views and estimates and could be construed as forward-looking statements. The future involves certain risks and uncertainties and could cause actual results to differ materially from the current views being expressed. Potential risks and uncertainties include factors such as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.
